Technical Analysis for VYNE - VYNE Therapeutics Inc.

Grade Last Price % Change Price Change
B 2.65 -2.57% -0.07
VYNE closed down 2.57 percent on Friday, November 1, 2024, on 71 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Nov 11
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Hammer Candlestick Bullish -2.57%
180 Bullish Setup Bullish Swing Setup -2.57%
Calm After Storm Range Contraction -2.57%
Wide Bands Range Expansion -2.57%
Overbought Stochastic Strength -2.57%
Calm After Storm Range Contraction -2.93%
NR7 Range Contraction -2.93%
Upper Bollinger Band Walk Strength -2.93%

   Recent Intraday Alerts

Alert Time
10 DMA Support about 18 hours ago
Down 3% about 20 hours ago
Down 2 % about 21 hours ago
Down 1% about 22 hours ago
60 Minute Opening Range Breakdown about 23 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

VYNE Therapeutics Inc. Description

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is headquartered in Bridgewater, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Autoimmune Disease Dermatology Psoriasis Atopic Dermatitis Acne Dermatitis Rosacea Acne Vulgaris Pruritus Prurigo Prurigo Nodularis

Is VYNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.45
52 Week Low 1.59
Average Volume 60,930
200-Day Moving Average 2.19
50-Day Moving Average 2.04
20-Day Moving Average 2.30
10-Day Moving Average 2.62
Average True Range 0.16
RSI (14) 67.21
ADX 50.78
+DI 30.66
-DI 11.82
Chandelier Exit (Long, 3 ATRs) 2.36
Chandelier Exit (Short, 3 ATRs) 2.29
Upper Bollinger Bands 3.00
Lower Bollinger Band 1.60
Percent B (%b) 0.75
BandWidth 60.73
MACD Line 0.22
MACD Signal Line 0.18
MACD Histogram 0.0367
Fundamentals Value
Market Cap 36.99 Million
Num Shares 14 Million
EPS -9.06
Price-to-Earnings (P/E) Ratio -0.29
Price-to-Sales 83.98
Price-to-Book 2.55
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.84
Resistance 3 (R3) 2.85 2.79 2.81
Resistance 2 (R2) 2.79 2.75 2.79 2.80
Resistance 1 (R1) 2.72 2.72 2.70 2.71 2.79
Pivot Point 2.67 2.67 2.65 2.66 2.67
Support 1 (S1) 2.60 2.62 2.57 2.59 2.51
Support 2 (S2) 2.54 2.59 2.54 2.50
Support 3 (S3) 2.47 2.54 2.49
Support 4 (S4) 2.46